Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study.

BACKGROUND: Helicobacter pylori may be found during upper gastrointestinal endoscopy (UGE) performed to diagnose celiac disease (CeD), inflammatory bowel disease (IBD), and eosinophilic esophagitis (EoE). We aimed to describe the frequency of H. pylori in children undergoing UGE for CeD, IBD, and EoE and the number of children receiving eradication treatment. MATERIALS AND METHODS: A retrospective multicenter study from 14 countries included pediatric patients diagnosed with CeD, IBD, and EoE between January 2019 and December 2021. DATA COLLECTED: age, gender, hematologic parameters, endoscopic, histologic, and H. pylori culture results, and information on eradication treatment. RESULTS: H. pylori was identified in 349/3890 (9%) children [167 (48%) male, median 12 years (interquartile range 8.1-14.6)]. H. pylori was present in 10% (173/1733) CeD, 8.5% (110/1292) IBD and 7.6% (66/865) EoE patients (p = NS). The prevalence differed significantly between Europe (Eastern 5.2% (28/536), Southern 3.8% (78/2032), Western 5.6% (28/513)) and the Middle East 26.6% (215/809) [odds ratio (OR) 7.96 95% confidence interval (CI) (6.31-10.1) p < 0.0001]. Eradication treatment was prescribed in 131/349 (37.5%) patients, 34.6% CeD, 35.8% IBD, and 56.1% EoE. Predictors for recommending treatment included erosions/ulcers [OR 6.45 95% CI 3.62-11.47, p < 0.0001] and nodular gastritis [OR 2.25 95% CI 1.33-3.81, p 0.003]. Treatment rates were higher in centers with a low H. pylori prevalence (<20%) [OR 3.36 95% CI 1.47-7.66 p 0.004]. CONCLUSIONS: Identifying H. pylori incidentally during UGE performed for the most common gastrointestinal diseases varies significantly among regions but not among diseases. The indications for recommending treatment are not well defined, and less than 40% of children received treatment.

Helicobacter pylori Found Incidentally During Upper Endoscopy Performed for Diagnosis of Common Pediatric Gastrointestinal Diseases.

BACKGROUND: Helicobacter pylori ( H. pylori ) gastritis may be an incidental finding during upper endoscopy performed to diagnose celiac disease (CeD), inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE). We aimed to describe the incidence of H. pylori in children undergoing endoscopy for CeD, IBD and EoE and determine the indications for treatment. METHODS: A retrospective, single-center study based on the review of endoscopy reports of pediatric patients, diagnosed with CeD, IBD and EoE, between January 2017 and December 2021. Data collected included; age, gender, hematologic parameters, endoscopic, histologic and H. pylori culture results, and information on eradication treatment. RESULTS: H. pylori gastritis was diagnosed in 120 of 558 (21.5%) children [72 (60%) female, mean age 10.6 years] during gastroscopy performed for the diagnosis of other GI diseases. H. pylori was present in 87 of 404 (21.5%) CeD, 27 of 113 (23.9%) IBD and 6 of 41 (14.6%) EOE patients ( P = 0.46). The main indication for treatment was the presence of ulcers, in 4 of 120 (3.3%), and erosions in 17 of 120 (14.2%). Eradication treatment was recommended in 22 of 120 (18.3%) patients, 8 of 87 (9.2%) CeD, 10 of 27 (37%) IBD and 4 of 6 (66.7%) EoE patients, P < 0.001. Four independent positive treatment predictors were identified; age above 10 years {odds ratio (OR) = 10.57 [95% confidence interval (CI) 1.88-59.36], P = 0.007} the presence of nodular gastritis (OR = 5.03 [95% CI 1.09-23.15], P = 0.38), erosions [OR = 49.21 (95% CI 8.19-295.83), P < 0.000] and ulcers [OR = 22.69 (95% CI 1.25-410.22), P = 0.035]. CeD was a strong negative predictor for treatment [OR = 0.23 (95% CI 0.002-0.241), P = 0.002]. CONCLUSIONS: H. pylori gastritis is a common incidental finding during endoscopy. The indications for treatment are not well defined and should be further investigated.

[METHICILLIN-RESISTANT VS. METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS (MRSA VS. MSSA) INFECTIONS IN CHILDREN IN SOUTHERN ISRAEL].

INTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of morbidity. Data regarding MRSA infections in children in Israel are scarce. OBJECTIVES: We assessed MRSA prevalence, risk factors and clinical manifestations in children with Staphylococcus aureus infections in southern Israel. METHODS: Our medical center is the sole hospital in southern Israel. All medical files of Staphylococcus aureus infections during the period 2005-2015, were reviewed retrospectively. RESULTS: Overall, 1,062 SA infections (MRSA; n=164, 15%) were identified; 687 (65%) skin and soft tissue infections (SSTI), and 375 (35%) invasive infections. MRSA was significantly more common in children <5 years (18% vs. 13% in children ≥5 years), Bedouin ethnicity (19% vs. 8% in Jewish children), burns (24% vs. 15%), congenital insensitivity to pain with anhidrosis (CIPA; 90% vs. 15%) and SSTI (17% vs. 12% in invasive infections). Blood count parameters and hospital-associated vs. community-acquired infection rates were similar comparing MRSA and Methicillin-susceptible Staphylococcus aureus (MSSA). In multivariate analysis, age (odds ratio, OR=0.953), Bedouin ethnicity (OR=2.698), burns (OR=2.036) and SSTI (OR=1.674) were associated with MRSA. MRSA isolates were more frequently resistant than MSSA to clindamycin (30% vs. 14%), erythromycin (34% vs. 15%), co-trimoxazole, tetracycline, rifampicin, ciprofloxacin and gentamicin (4% vs. 0.5%, all). All isolates were vancomycin susceptible. CONCLUSIONS: MRSA infections are common in young, Bedouin children and burns, and are more commonly multidrug resistant than MSSA in our region. Our data should be used to better identify and treat children with MRSA infection.